NCT03816345 2026-04-21
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
18 trialsNCT07532902 2026-04-16
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06049576 2026-04-15
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02453620 2026-04-13
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02496208 2026-04-13
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT03502733 2026-04-13
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03816358 2026-04-13
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04840589 2026-04-13
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06508463 2026-04-13
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT07134842 2026-04-09
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT02668770 2026-04-07
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07401875 2026-04-02
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07075120 2026-03-31
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Not yet recruiting
NCT03860272 2026-03-30
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
NCT05254184 2026-03-30
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT05536141 2026-03-30
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT07501117 2026-03-30
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Herlev Hospital
Phase 1 Not yet recruiting